Effect and Safety of Mycophenolate Mofetil or Sodium in Systemic Sclerosis-Associated Interstitial Lung Disease: A Meta-Analysis

Table 1

Baseline characteristics of the patients included per study.

Study/year	Number of patients	Age (years)	Female	Prior cytotoxic treatment received	Diffuse SSc	Disease duration (years)
Liossis et al., 2006 [27]	6	46	4/6	1/6	4/6	3.4
Gerbino et al., 2008 [25]	13	52	5/13	9/13	9/13	5
Koutroumpas et al., 2010 [26]	10	59	8/10	NA	10/10	7.7
Zamora et al., 2008 [28]	17	51	10/17	NA	15/17	2
Simeon-Aznar, 2011 [24]	14	54	13/14	10/14	8/14	6.5
Tzouvelekis et al., 2012	10	56	4/10	6/10	10/10	1.5
Total	69	53	44/69	26/42	56/69	4.7

Data are presented as mean unless otherwise stated.
Abbreviations: SSc: systemic sclerosis and NA: nonapplicable.